List of Silenor drug patents
Silenor is owned by Currax.
Silenor contains Doxepin Hydrochloride.
Silenor has a total of 15 drug patents out of which 0 drug patents have expired.
Silenor was authorised for market use on 17 March, 2010.
Silenor is available in tablet;oral dosage forms.
Silenor can be used as treatment of insomnia.
The generics of Silenor are possible to be released after 07 September, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10653662 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(4 years from now) | |
| US9486437 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(4 years from now) | |
| US9861607 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(4 years from now) | |
| US10238620 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(4 years from now) | |
| US10653660 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Jul, 2027
(4 years from now) | |
| US11110074 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Jul, 2027
(4 years from now) | |
| US9572814 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Jul, 2027
(4 years from now) | |
| US7915307 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Aug, 2027
(4 years from now) | |
| US11234954 | CURRAX | Low-dose doxepin for treatment of sleep disorders in elderly patients |
Jan, 2028
(4 years from now) | |
| US9907780 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Apr, 2028
(5 years from now) | |
| US10548871 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Apr, 2028
(5 years from now) | |
| US11096920 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Apr, 2028
(5 years from now) | |
| US9107898 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2028
(5 years from now) | |
| US9532971 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Jun, 2029
(6 years from now) | |
| US8513299 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
Sep, 2030
(7 years from now) | |
Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient
Market Authorisation Date: 17 March, 2010
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
SILENOR family patents
54
United States
5
Japan
4
Canada
2
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic